查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2101652

畜牧治療藥物和疫苗的市場機會、成長要素、產業趨勢以及 2026-2035 年預測。

Livestock Therapeutics and Vaccines Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026 - 2035
出版日期: | 出版商: Global Market Insights Inc. | 英文 135 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

全球畜牧治療和疫苗市場預計到 2025 年將達到 182 億美元，年複合成長率為 5.6%，到 ​​2035 年將達到 315 億美元。

畜牧治療及疫苗市場-IMG1

全球畜牧業面臨的感染疾病、寄生蟲病和生產相關健康挑戰日益增多，推動了畜牧治療和疫苗市場的成長。對有效疾病預防和治療方案的需求不斷成長，整體了動物醫藥和動物保健技術的持續創新。生物製藥、疫苗研發、動物醫藥、診斷技術、精準動物保健和現代畜牧管理系統的進步，正在提高疾病預防、治療效率和畜群整體健康狀況。同時，製劑技術和預防保健方法的改進，使畜牧養殖戶能夠在提高治療依從性的同時，減少運作方面的挑戰。數位化動物保健管理、精密農業實踐和先進育種方案的日益普及，正在加強疾病監測，並支持更積極主動的畜牧保健策略。預計對創新動物用藥品、預防性藥物和下一代生物製藥的持續投資，將在整個預測期內維持市場擴張。此外，商業性畜牧業生產增加、醫療保健領域支出成長、加強防治動物疾病以及提高人們對合理使用抗菌藥物的認知，都將繼續推動全球畜牧治療和疫苗市場的長期成長。

市場範圍
開始年份 2025
預測期 2026-2035
上市時的市場規模 182億美元
預測金額 315億美元
複合年成長率 5.6%

預計到2025年，治療藥物業務的銷售額將達到111億美元。隨著畜牧養殖戶日益重視維護動物健康、提高生產力、降低死亡率和減少經濟損失，對獸藥產品的強勁需求將持續支撐該業務的成長。獸藥在商業性畜牧系統中的廣泛應用將進一步鞏固治療藥物業務在預測期內的市場地位。

預計到2025年，細菌性疾病市場規模將達到47億美元。畜群疾病流行率的不斷上升持續推動動物用藥品、預防性疫苗和診斷解決方案的需求，這些產品旨在改善動物健康。同時，人們越來越重視合理使用抗菌藥物，這加速了更安全、更具針對性的療法的研發，並加強了整個畜牧業的疾病控制措施。

預計到2025年，北美畜牧治療和疫苗市場將佔據40%的市場佔有率，並在2035年之前以5.3%的複合年成長率成長。該地區的成長得益於完善的動物保健體系、大規模的商業化畜牧生產以及有利於疾病預防和動物健康管理的監管措施。對獸醫研究、創新生技藥品、先進疫苗和治療產品的持續投資預計將進一步加速全部區域市場的擴張。

目錄

第1章：調查方法和範圍

第2章執行摘要

第3章 行業洞察

  • 產業生態系分析
  • 影響產業的因素
    • 促進因素
      • 感染疾病和跨國動物疾病發生率上升
      • 全球對肉類、牛奶、雞蛋和其他動物性產品的需求不斷成長
      • 擴大疫苗接種和牲畜健康管理計劃的實施範圍。
      • 商業性畜牧業的擴張和密集畜牧業養殖系統的推廣
    • 產業潛在風險與挑戰
      • 對肉類。
      • 動物用藥品的法規核准流程非常嚴格。
    • 市場機遇
      • 增加對水產養殖治療藥物和魚類疫苗的投資
      • 擴大長效注射藥物和下一代生物製藥的應用
  • 成長潛力分析
  • 技術展望
    • 目前技術
    • 新興技術
  • 價格趨勢分析
    • 過去的價格趨勢
    • 價格趨勢分析：依產品類型
  • 監理情勢
  • 波特的分析
  • PESTLE分析
  • 產品平臺分析
  • 人工智慧和生成式人工智慧對市場的影響
  • 未來市場趨勢

第4章 競爭情勢

  • 介紹
  • 企業市佔率分析
    • 世界
    • 北美洲
    • 歐洲
  • 企業矩陣分析
  • 主要市場公司的競爭分析
  • 競爭定位矩陣
  • 主要進展
    • 併購
    • 夥伴關係和聯盟
    • 新產品發布
    • 業務拓展計劃

第5章 市場估算與預測：依產品類型分類，2022-2035年

  • 治療
    • 抗生素/感染疾病物
    • 抗寄生蟲藥物
    • 抗發炎藥
    • 皮質類固醇
    • 鎮靜劑
    • 心血管藥物
    • 消化器官系統藥物
    • 其他治療方法
  • 疫苗
    • 減毒活疫苗
    • 去活化疫苗
    • 重組疫苗和次單位疫苗
    • 類毒素疫苗
    • 其他疫苗

第6章 市場估計與預測：依動物類型分類，2022-2035年

  • 家禽
  • 牛
  • 豬
  • 綿羊和山羊
  • 水產養殖
  • 其他動物類型

第7章 市場估計與預測：依疾病適應症分類，2022-2035年

  • 細菌性疾病
  • 病毒性疾病
  • 寄生蟲病
  • 黴菌感染疾病
  • 其他疾病指徵

第8章 市場估計與預測：依給藥途徑分類，2022-2035年

  • 注射劑（腸外給藥）
  • 口服
  • 外用
  • 鼻內/吸入
  • 其他給藥途徑

第9章 市場估價與預測：依通路分類，2022-2035年

  • 獸藥
  • 電子商務
  • 零售藥房
  • 其他分銷管道

第10章 市場估價與預測：依地區分類，2022-2035年

  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 荷蘭
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • UAE

第11章：公司簡介

  • Zoetis
  • Merck Animal Health（MSD Animal Health）
  • Boehringer Ingelheim Animal Health
  • Elanco Animal Health
  • Ceva Sante Animale
  • Virbac
  • HIPRA
  • Vetoquinol
  • Phibro Animal Health
  • Indian Immunologicals
  • Vaxxinova
  • Biogenesis Bago
  • Bioveta
  • Neogen Corporation
  • Norbrook
簡介目錄
Product Code: 16248

The Global Livestock Therapeutics & Vaccines Market was valued at USD 18.2 billion in 2025 and is estimated to grow at a CAGR of 5.6% to reach USD 31.5 billion by 2035.

Livestock Therapeutics and Vaccines Market - IMG1

Growth in the livestock therapeutics & vaccines market is driven by the increasing occurrence of infectious illnesses, parasitic conditions, and production-related health challenges affecting livestock populations worldwide. Rising demand for effective disease prevention and treatment solutions has encouraged continuous innovation across veterinary pharmaceuticals and animal health technologies. Advancements in biologics, vaccine development, veterinary therapeutics, diagnostic capabilities, precision animal healthcare, and modern livestock management systems are improving disease prevention, treatment efficiency, and overall herd health. At the same time, improvements in formulation technologies and preventive healthcare approaches are helping livestock producers enhance treatment compliance while reducing operational challenges. Greater adoption of digital animal health management, precision farming practices, and advanced breeding programs is strengthening disease surveillance and supporting more proactive livestock healthcare strategies. Continued investments in innovative veterinary medicines, preventive healthcare products, and next-generation biologics are expected to sustain market expansion throughout the forecast period. In addition, increasing commercial livestock production, higher spending on veterinary healthcare, expanding animal disease control initiatives, and growing awareness of responsible antimicrobial use continue to reinforce long-term growth across the global livestock therapeutics & vaccines market.

Market Scope
Start Year2025
Forecast Year2026-2035
Start Value$18.2 Billion
Forecast Value$31.5 Billion
CAGR5.6%

The therapeutics segment generated USD 11.1 billion in 2025. Strong demand for veterinary treatment products continues to support segment growth as livestock producers increasingly focus on maintaining herd health, improving productivity, reducing mortality, and minimizing economic losses. The expanding adoption of veterinary pharmaceuticals across commercial livestock production systems continues to strengthen the market position of the therapeutics segment throughout the forecast period.

The bacterial diseases segment was valued at USD 4.7 billion in 2025. Increasing disease prevalence across livestock populations continues to support demand for veterinary medicines, preventive vaccines, and diagnostic solutions designed to improve animal health outcomes. At the same time, greater emphasis on responsible antimicrobial use is encouraging the development of safer, more targeted treatment options while strengthening disease management practices across the livestock industry.

North America Livestock Therapeutics & Vaccines Market accounted for 40% share in 2025 and is anticipated to grow at a CAGR of 5.3% through 2035. Regional growth is supported by a well-established animal healthcare ecosystem, extensive commercial livestock production, and favorable regulatory initiatives focused on disease prevention and animal health management. Continued investment in veterinary research, innovative biologics, advanced vaccines, and therapeutic products is expected to further strengthen market expansion across the region.

Major companies operating in the global livestock therapeutics & vaccines market include Zoetis, Merck Animal Health (MSD Animal Health), Boehringer Ingelheim Animal Health, Elanco Animal Health, Ceva Sante Animale, Virbac, HIPRA, Vetoquinol, Phibro Animal Health, Indian Immunologicals, Vaxxinova, Biogenesis Bago, Bioveta, Neogen Corporation, and Norbrook. Companies operating in the livestock therapeutics & vaccines market are strengthening their market position by expanding research and development activities, enhancing biologics and vaccine portfolios, and introducing advanced veterinary therapeutics that improve disease prevention and treatment outcomes. Many manufacturers are increasing investments in innovative production technologies, expanding manufacturing capacity, and improving product quality to address growing global demand. Strategic collaborations, acquisitions, licensing agreements, and distribution partnerships continue to support geographic expansion and broaden customer reach.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definition
  • 1.2 Research approach
  • 1.3 Quality commitments
    • 1.3.1 GMI AI policy and data integrity commitment
      • 1.3.1.1 Source consistency protocol
  • 1.4 Research trail and confidence scoring
    • 1.4.1 Research trail components
    • 1.4.2 Scoring components
  • 1.5 Data collection
    • 1.5.1 Partial list of primary sources
  • 1.6 Data mining sources
    • 1.6.1 Paid sources
      • 1.6.1.1 Sources, by region
  • 1.7 Base estimates and calculations
    • 1.7.1 Revenue share analysis
    • 1.7.2 Base year calculation
  • 1.8 Forecast model
  • 1.9 Research transparency addendum
    • 1.9.1 Source attribution framework
    • 1.9.2 Quality assurance metrics
    • 1.9.3 Our commitment to trust

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis
  • 2.2 Key market trends
    • 2.2.1 Regional trends
    • 2.2.2 Product type trends
    • 2.2.3 Animal type trends
    • 2.2.4 Disease indication trends
    • 2.2.5 Route of administration trends
    • 2.2.6 Distribution channel trends
  • 2.3 CXO perspectives: Strategic imperatives

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising prevalence of infectious and transboundary animal diseases
      • 3.2.1.2 Growing global demand for meat, milk, eggs, and other animal-derived products
      • 3.2.1.3 Increasing adoption of preventive vaccination and herd health management programs
      • 3.2.1.4 Expansion of commercial livestock farming and intensive animal production systems
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 Regulatory restrictions on antimicrobial use in food animals
      • 3.2.2.2 Stringent regulatory approval processes for veterinary products
    • 3.2.3 Market opportunities
      • 3.2.3.1 Increasing investment in aquaculture therapeutics and fish vaccines
      • 3.2.3.2 Rising adoption of long-acting injectable therapeutics and next-generation biologics
  • 3.3 Growth potential analysis
  • 3.4 Technology landscape
    • 3.4.1 Current technology
    • 3.4.2 Emerging technologies
  • 3.5 Pricing trend analysis (Driven by Primary Research)
    • 3.5.1 Historical pricing trends
    • 3.5.2 Pricing trend analysis, by product type
  • 3.6 Regulatory landscape (Driven by primary research)
    • 3.6.1 North America
    • 3.6.2 Europe
    • 3.6.3 Asia Pacific
    • 3.6.4 Latin America
    • 3.6.5 Middle East and Africa
  • 3.7 Porter's analysis
  • 3.8 PESTEL analysis
  • 3.9 Product pipeline analysis (Driven by Primary Research)
  • 3.10 Impact of AI and generative AI on the market
  • 3.11 Future market trends (Driven by primary research)

Chapter 4 Competitive Landscape, 2025

  • 4.1 Introduction
  • 4.2 Company market share analysis
    • 4.2.1 Global
    • 4.2.2 North America
    • 4.2.3 Europe
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Key developments
    • 4.6.1 Merger and acquisition
    • 4.6.2 Partnership and collaboration
    • 4.6.3 New product launches
    • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Product Type, 2022 - 2035 ($ Mn)

  • 5.1 Key trends
  • 5.2 Therapeutics
    • 5.2.1 Antibiotics/anti-infectives
    • 5.2.2 Antiparasitics agents
    • 5.2.3 Anti-inflammatory agents
    • 5.2.4 Corticosteroids
    • 5.2.5 Tranquilizers
    • 5.2.6 Cardiovascular drugs
    • 5.2.7 Gastrointestinal drugs
    • 5.2.8 Other therapeutics
  • 5.3 Vaccines
    • 5.3.1 Live attenuated vaccines
    • 5.3.2 Inactivated vaccines
    • 5.3.3 Recombinant & subunit vaccines
    • 5.3.4 Toxoid vaccines
    • 5.3.5 Other vaccines

Chapter 6 Market Estimates and Forecast, By Animal Type, 2022 - 2035 ($ Mn)

  • 6.1 Key trends
  • 6.2 Poultry
  • 6.3 Cattle
  • 6.4 Swine
  • 6.5 Sheep and goats
  • 6.6 Aquaculture
  • 6.7 Other animal types

Chapter 7 Market Estimates and Forecast, By Disease Indication, 2022 - 2035 ($ Mn)

  • 7.1 Key trends
  • 7.2 Bacterial diseases
  • 7.3 Viral diseases
  • 7.4 Parasitic diseases
  • 7.5 Fungal diseases
  • 7.6 Other disease indications

Chapter 8 Market Estimates and Forecast, By Route of Administration, 2022 - 2035 ($ Mn)

  • 8.1 Key trends
  • 8.2 Injectable (parenteral)
  • 8.3 Oral
  • 8.4 Topical
  • 8.5 Intranasal/inhalation
  • 8.6 Other route of administration

Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2022 - 2035 ($ Mn)

  • 9.1 Key trends
  • 9.2 Veterinary hospital pharmacies
  • 9.3 E-commerce
  • 9.4 Retail pharmacies
  • 9.5 Other distribution channels

Chapter 10 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)

  • 10.1 Key trends
  • 10.2 North America
    • 10.2.1 U.S.
    • 10.2.2 Canada
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 France
    • 10.3.4 Spain
    • 10.3.5 Italy
    • 10.3.6 Netherlands
  • 10.4 Asia Pacific
    • 10.4.1 China
    • 10.4.2 Japan
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 South Korea
  • 10.5 Latin America
    • 10.5.1 Brazil
    • 10.5.2 Mexico
    • 10.5.3 Argentina
  • 10.6 Middle East and Africa
    • 10.6.1 South Africa
    • 10.6.2 Saudi Arabia
    • 10.6.3 UAE

Chapter 11 Company Profiles

  • 11.1 Zoetis
  • 11.2 Merck Animal Health (MSD Animal Health)
  • 11.3 Boehringer Ingelheim Animal Health
  • 11.4 Elanco Animal Health
  • 11.5 Ceva Sante Animale
  • 11.6 Virbac
  • 11.7 HIPRA
  • 11.8 Vetoquinol
  • 11.9 Phibro Animal Health
  • 11.10 Indian Immunologicals
  • 11.11 Vaxxinova
  • 11.12 Biogenesis Bago
  • 11.13 Bioveta
  • 11.14 Neogen Corporation
  • 11.15 Norbrook